Skip to main content
Clinical Trials/NCT01528319
NCT01528319
Completed
Not Applicable

Open Clinical Trial of Arthroscopic Bankart Repair Using MG-1 for Dislocation of the Shoulder

Johnson & Johnson K.K. Medical Company0 sites24 target enrollmentDecember 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Shoulder Dislocation
Sponsor
Johnson & Johnson K.K. Medical Company
Enrollment
24
Primary Endpoint
Surgery Success
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

To evaluate the efficacy and safety of arthroscopic Bankart repair using MG-1 for dislocation of shoulder

Registry
clinicaltrials.gov
Start Date
December 2011
End Date
November 2012
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Johnson & Johnson K.K. Medical Company
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with dislocation of the shoulder and indicated for arthroscopic Bankart repair
  • Patients of 16 years or older
  • Patients who understand the contents of the study and from whom a written consent can be obtained
  • Patients who can visit the hospital for follow-ups after surgery

Exclusion Criteria

  • Patients with serious complications
  • Patients with comminuted fracture which may prevent fixation of the anchors
  • Patients with the following diseases or conditions which may delay healing
  • Lack of blood, infection, etc.
  • Psychiatric disorder, alcohol poisoning, drug toxicity, etc.
  • Tissues around the surgical site are not healthy under steroid therapy or chemotherapy
  • Patients with epilepsy or bone disease (cystic change, osteopenia, etc.)
  • Patients with dementia
  • Patients with a history of allergy to glycolic acid, poly-L-lactic acid, β-tricalcium phosphate, polyethylene or polydioxane
  • Patients who cannot undergo general anesthesia

Outcomes

Primary Outcomes

Surgery Success

Time Frame: 12 weeks after surgery

The rate of successful cases when surgery success is defined as "Procedure success is confirmed, the anchors are confirmed to be in the burr holes by the MRI examination, the glenohumeral ligament labral complex is maintained at the anterior edge of the glenoid cavity at 12 weeks after surgery, and there is no need of retreatment"

Clinical Function Evaluation

Time Frame: 12 weeks

To evaluate the Japan Shoulder Society Shoulder Instability Score (JSS-SIS) and Rowe Score at 12 weeks after surgery JSS-SIS Score (subscales are summed, higher values represent a better outcome): * Pain (0 to 20) * Function (0 to 20) * Range of Motion (0 to 20) * Evaluation of X-ray findings (0 to 10) * Stability (0 to 30) Rowe Score (subscales are summed, higher values represent a better outcome): * Stability (0 to 50) * Motion (0 to 20) * Function (0 to 30)

Secondary Outcomes

  • Procedure Success(12 weeks)
  • Number of Participants With Abnormal Changes in One or More Laboratory Tests(12 weeks and 24 weeks after surgery)
  • Clinical Function Evaluation(24 weeks)
  • Adverse Event Evaluation(Between the time of obtainment of consent and 24 weeks after surgery)

Similar Trials